预约演示
更新于：2025-04-14
Tamsulosin Hydrochloride
盐酸坦洛新
更新于：2025-04-14
概要
基本信息
简介坦索罗辛于1997年在美国被批准用于医疗用途。具体而言，它是一种α1肾上腺素能受体阻滞剂。 以 Flomax 等品牌名称销售的坦索罗辛是一种用于治疗症状性良性前列腺增生 (BPH) 和慢性前列腺炎并帮助排出肾结石的药物。 当结石较大时，肾结石获益的证据更好。 它是通过嘴巴服用的。 常见的副作用包括头晕、头痛、失眠、恶心、视力模糊和性问题。 其他副作用可能包括站立时头晕目眩和血管性水肿。 坦索罗辛是一种α受体阻滞剂，通过放松前列腺肌肉起作用。坦索罗辛于1997年在美国被批准用于医疗用途。具体而言，它是一种α1肾上腺素能受体阻滞剂。 以 Flomax 等品牌名称销售的坦索罗辛是一种用于治疗症状性良性前列腺增生 (BPH) 和慢性前列腺炎并帮助排出肾结石的药物。 当结石较大时，肾结石获益的证据更好。 它是通过嘴巴服用的。 常见的副作用包括头晕、头痛、失眠、恶心、视力模糊和性问题。 其他副作用可能包括站立时头晕目眩和血管性水肿。 坦索罗辛是一种α受体阻滞剂，通过放松前列腺肌肉起作用。 |
药物类型 小分子化药 |
别名 (-)-tamsulosin、(R)-(-)-tamsulosin、(R)-5-(2-((2-(2-ethoxyphenoxy)ethyl)amino)propyl)-2-methoxybenzenesulfonamide + [36] |
靶点 |
作用方式 拮抗剂 |
作用机制 α1A-AR拮抗剂(肾上腺素能受体α-1a拮抗剂) |
最高研发阶段批准上市 |
首次获批日期 日本 (1993-07-02), |
最高研发阶段(中国)批准上市 |
特殊审评优先审评 (中国) |
登录后查看时间轴
结构/序列
分子式C20H29ClN2O5S |
InChIKeyZZIZZTHXZRDOFM-XFULWGLBSA-N |
CAS号106463-17-6 |
关联
316
项与 盐酸坦洛新 相关的临床试验NCT06803030
A Comparative Study on the Efficacy of Tamsulosin, Solifenacin and Mirabegron in Alleviating Ureteral Stent-related Symptoms: a Randomized Controlled Trial
NCT06865430
Management of Dysuria and Irritative Symptoms After HoLEP: a Prospective Study Evaluating the Efficacy of Alpha-Blocker Therapy
NCT06843538
Peri-operative Tamsulosin and Impact on Voiding Trial Following Outpatient Urogynecology Surgery: a Randomized Controlled Trial
100 项与 盐酸坦洛新 相关的临床结果
登录后查看更多信息
100 项与 盐酸坦洛新 相关的转化医学
登录后查看更多信息
100 项与 盐酸坦洛新 相关的专利（医药）
登录后查看更多信息
3,052
项与 盐酸坦洛新 相关的文献（医药）2025-06-01AMERICAN JOURNAL OF OPHTHALMOLOGY
Unplanned Return to the Operating Room After Cataract Surgery
Article
作者: Suazo, Mallory K ; Akhlaq, Anam ; Khan, Malik Muhammad Hamza ; Ali, Muhammad ; Schein, Oliver D ; Woreta, Fasika A
PURPOSE:
To determine the rate of unplanned return to the operating room (OR) within 90 days of cataract surgery and to identify the most common preoperative and intraoperative risk factors.
DESIGN:
Retrospective case-control study.
SUBJECTS AND CONTROLS:
Patients aged ≥40 years undergoing cataract surgery at the Wilmer Eye Institute between 2019 and 2022 with at least 90 days of postoperative follow-up were included. Patients with return to the OR for a reason other than a postoperative complication of cataract surgery in the same eye were excluded. For each case, a time-matched control (cataract surgery within 1 month of the case's surgery) was selected using a random number generator.
METHODS:
The chi-squared test was used for categorical variables, the student's t-test for continuous variables, and the multivariable logistic regression analysis to assess for associated preoperative and intraoperative factors.
MAIN OUTCOME MEASURES:
The main outcomes included the rate and the most common reasons for unplanned return to the OR as well as the odds ratios of associated preoperative and intraoperative variables.
RESULTS:
Among 32,480 eyes, 175 eyes (0.54%) had an unplanned return to the OR within 21 ± 21 days of cataract surgery. The most common reason was retained lens fragments in 88 eyes (50%). Patients with an unplanned return to the OR had a worse mean best-corrected visual acuity preoperatively (Snellen equivalent of ∼20/100 for cases vs 20/50 for controls, p-value < .001) and at last follow-up (cases 20/50, controls 20/30, p-value < .001). There were significantly higher odds of an unplanned return to the OR for patients undergoing complex cataract surgery (odds ratio, 1.80; 95% CI, 1.06-3.05) and for patients with prior tamsulosin use (odds ratio, 2.00; 95% CI, 1.09-3.69).
CONCLUSIONS:
Patients undergoing complex cataract surgery and those with prior tamsulosin use had significantly higher odds of unplanned return to the OR. Monitoring rates of unplanned return to the OR at the institutional and national levels by using national clinical registries or a multicenter study is needed to assist in quality monitoring and to improve patient surgical outcomes.
2025-05-01DRUG SAFETY
Network Analysis and Machine Learning for Signal Detection and Prioritization Using Electronic Healthcare Records and Administrative Databases: A Proof of Concept in Drug-Induced Acute Myocardial Infarction
Article
作者: Ágg, Bence ; Ferdinandy, Péter ; Balogh, Olivér M ; Spina, Edoardo ; Sessa, Maurizio ; Battini, Vera ; Casula, Manuela ; Rossi, Andrea ; Barbieri, Maria Antonietta ; Abate, Andrea ; Carnovale, Carla ; Pétervári, Mátyás ; Cocco, Marianna
BACKGROUND:
Safety signals for potential drug-induced adverse events (AEs) typically emerge from multiple data sources, primarily spontaneous reporting systems, despite known limitations. Increasingly, real-world data from sources such as electronic health records (EHRs) and administrative databases are leveraged for signal detection. Although network analysis has shown promise in mapping relationships between clinical attributes for signal detection in spontaneous reporting system databases, its application in real-world data from EHRs and administrative databases remains limited.
OBJECTIVE:
This study aimed to evaluate the performance of network analysis in detecting safety signals within Italian administrative databases, using drug-induced acute myocardial infarction (AMI) as a proof of concept.
METHODS:
We employed a case-crossover design to explore the association between drug exposure and AMI using the Healthcare Administrative Database of Mantova, Italy, from 2014 to 2018. Patients with their first AMI hospitalization were identified after a 365-day washout period to exclude prior hospitalizations. We constructed a network to analyse the relationships between prescribed drugs and diagnoses, represented as nodes, with undirected edges illustrating their interactions. For each patient with AMI, we identified all diagnoses and drugs recorded or redeemed within 365 days of the first AMI episode and generated various drug-diagnosis, drug-drug, and diagnosis-diagnosis pairs. We calculated the frequency of these pairs, and three types of edge weights quantified the strength of connections. We identified outlier drug-AMI pairs using a predictive score (F) based on frequency (C) and full edge weights (WF), with validation for known AMI associations. We prioritized signals using the F score, C of AMI, and WF, analysed through k-means clustering to identify patterns in the data.
RESULTS:
From 2014 to 2018, a total of 3918 patients had an AMI, with 4686 AMI diagnoses. Of those, 2866 had prescriptions in the previous year, totalling 498,591 prescriptions. A network analysis identified 2968 unique nodes, revealing 529,935 diagnosis-diagnosis connections, 235,380 drug-diagnosis connections, and 102,831 drug-drug connections. The median number of connections (C) was 404 (Q1-Q3: 194-671) for drug nodes and 380 (Q1-Q3: 216-664) for diagnosis nodes. The median WF was 11.8 (Q1-Q3: 9-14), and the median F score across pairs was 0.1 (Q1-Q3: 0.1-0.3). A total of 249 potential safety signals were detected, with 63.4% aligning with known AEs. Among the remaining signals, 80 were prioritized, and five emerged as the highest priority: terazosin, tamsulosin, allopurinol, esomeprazole, and omeprazole.
CONCLUSIONS:
Overall, our novel method demonstrates that network analysis is a valuable tool for signal detection and prioritization in drug-induced AEs based on EHRs and administrative databases.
2025-04-03Drug metabolism and personalized therapy
CYP2D6 genetic polymorphisms impact on tamsulosin efficacy and safety in patients with benign prostatic hyperplasia
Article
作者: Abdullaev, Shokhrukh ; Teodorovich, Oleg ; Sychev, Dmitry ; Bochkov, Pavel ; Sychev, Ivan ; Shatokhin, Maksim ; Abdullaev, Sherzod ; Tuchkova, Svetlana ; Loran, Oleg ; Krasnov, Aleksandr
Abstract:
Objectives:
The clinical outcomes of tamsulosin therapy for LUTS/BPH patients vary, with up to one-third of patients reporting unsatisfactory results. Enhancing the effectiveness and safety of tamsulosin therapy for LUTS/BPH patients remains a significant challenge in current medical practice. Limited data exists regarding the impact of CYP2D6 genetic polymorphisms on the efficacy and safety of tamsulosin therapy. Given that tamsulosin is metabolized by CYP2D6, variations in this enzyme may influence the drug's pharmacodynamic response. The objective of this study was to evaluate the impact of CYP2D6 pharmacogenetic markers on tamsulosin efficacy and safety in patients with LUTS associated with BPH.
Methods:
The study included 142 male patients with LUTS and a confirmed diagnosis of BPH (N40 ICD-10). Patients were followed for a minimum of 8 weeks and underwent four examinations (at days 0, 14, 28, and 56). Treatment efficacy was assessed using the IPSS with quality of life assessment, transrectal ultrasound of the prostate with estimation of prostate volume and residual urine volume, and maximum urinary flow rate (Qmax). Allelic variants of CYP2D6 (*2, *3, *4, *6, *9, *10, and *41) were determined by polymerase chain reaction in all patients..
Results:
In the subgroup with moderate symptoms, individuals classified as poor and intermediate metabolizers exhibited significantly higher ΔQmax compared to normal metabolizers (4.25 [2.5; 6.1] vs. [0.6; 4.3], p=0.001826). Moreover, carriers of the CYP2D6*10 CT heterozygous genotype demonstrated lower IPSS scores at the last two visits compared to those with the CC genotype (visit 3: −7.45 ± 3.93 vs. −5.25 ± p=0.05; visit 4: −8.91 ± 3.88 vs. −6.31 ± 5.7), as well as reduced IPSS irritative symptoms at visit 2 (−3.87 ± 2.70 vs −2.47 ± 3.1, p=0.05), and a significant increase in ΔQmax ([2.5; 5.9] vs. [0.6; 4.7], p=0.01). In the subgroup with severe symptoms, individuals with CYP2D6*41 GA + AA genotypes exhibited less residual urine volume following therapy compared to those with the GG genotype ([15.0; 32.0] vs. [3.0; 19.0], p=0.007029). The CYP2D6 polymorphic variants did not impact the tamsulosin safety. The study did not reach the estimated power for CYP2D6*3, CYP2D6*6, and CYP2D6*9 polymorphisms due to their low frequency of occurrence in the study population. The multivariate logistic regression model indicated that potential predictors of tamsulosin therapy efficacy in LUTS/BPH patients may include BMI (p<0.001), prostate volume (p<0.002), as well as the carriage of CYP2D6*4 (p<0.001) and CYP2D6*10 (p=0.012) markers. The model explained 81.9 % of the variance in the predicted outcome and accurately forecasted tamsulosin therapy efficacy in BPH with a precision of 92.1 %.
Conclusions:
The present study identified potential markers that could serve as predictors of the effectiveness of tamsulosin. Specifically, genetic markers such as CYP2D6*4, CYP2D6*10, CYP2D6*41, and non-genetic factors like BMI and prostate volume were associated with the clinical efficacy of tamsulosin therapy in LUTS/BPH patients..
100 项与 盐酸坦洛新 相关的药物交易
登录后查看更多信息
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 下尿路症状 | 比利时 | 2005-03-01 | |
| 下尿路症状 | 卢森堡 | 2005-03-01 | |
| 高血压 | 美国 | 1997-04-15 | |
| 前列腺增生症 | 日本 | 1993-07-02 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 泌尿系统表现 | 临床3期 | 美国 | 2015-09-23 | |
| 神经性膀胱功能障碍 | 临床3期 | 美国 | 2008-01-01 | |
| 神经性膀胱功能障碍 | 临床3期 | 比利时 | 2008-01-01 | |
| 神经性膀胱功能障碍 | 临床3期 | 巴西 | 2008-01-01 | |
| 神经性膀胱功能障碍 | 临床3期 | 德国 | 2008-01-01 | |
| 神经性膀胱功能障碍 | 临床3期 | 印度 | 2008-01-01 | |
| 神经性膀胱功能障碍 | 临床3期 | 意大利 | 2008-01-01 | |
| 神经性膀胱功能障碍 | 临床3期 | 墨西哥 | 2008-01-01 | |
| 神经性膀胱功能障碍 | 临床3期 | 菲律宾 | 2008-01-01 | |
| 神经性膀胱功能障碍 | 临床3期 | 俄罗斯 | 2008-01-01 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
临床4期 | 5 | (Hyoscyamine) | 遞積齋遞齋襯憲蓋構願(醖積壓餘築糧夢範醖鹹) = 襯積願範網鹽醖積廠選 獵窪廠艱廠糧憲齋選淵 (範糧選製鏇壓構選顧觸, 繭鑰網艱糧衊簾顧艱積 ~ 襯遞襯築鬱鬱夢繭醖夢) 更多 | - | 2024-12-03 | ||
(Tamsulosin) | 遞積齋遞齋襯憲蓋構願(醖積壓餘築糧夢範醖鹹) = 廠製鹹襯選衊窪齋齋廠 獵窪廠艱廠糧憲齋選淵 (範糧選製鏇壓構選顧觸, 膚遞窪鏇鹽築鹹壓獵壓 ~ 糧鹹餘廠製積膚願鹽願) 更多 | ||||||
临床3期 | 90 | (Tamsulosin) | 鏇繭憲築遞鏇窪簾構構 = 鹽築範鑰願鏇襯夢鏇顧 顧襯範憲襯壓夢餘壓餘 (獵遞鑰鹹鏇憲壓壓壓簾, 願衊遞衊壓鹽糧廠蓋餘 ~ 壓鏇獵齋願齋顧鏇願廠) 更多 | - | 2024-05-30 | ||
Placebo (Placebo) | 鏇繭憲築遞鏇窪簾構構 = 觸鑰齋夢鬱鑰網構鑰獵 顧襯範憲襯壓夢餘壓餘 (獵遞鑰鹹鏇憲壓壓壓簾, 襯鑰獵製顧糧積鬱遞鏇 ~ 鹽選糧獵憲廠遞壓鬱夢) 更多 | ||||||
N/A | - | 200 | 廠鏇壓繭襯衊積選鏇觸(顧願繭壓遞製積憲衊齋) = 築選鬱襯壓顧淵鏇鹽範 齋顧醖遞齋繭鹹齋製構 (膚醖淵鏇憲願憲鹹淵顧 ) | 积极 | 2024-05-01 | ||
Placebo | 廠鏇壓繭襯衊積選鏇觸(顧願繭壓遞製積憲衊齋) = 顧齋窪鬱選獵鹹蓋淵廠 齋顧醖遞齋繭鹹齋製構 (膚醖淵鏇憲願憲鹹淵顧 ) | ||||||
临床2期 | 161 | (Tamsulosin- Intervention Group) | 鏇醖襯願糧淵範遞獵窪(壓網蓋鹽夢醖簾鹹選願) = 觸艱糧窪鬱遞夢鬱簾獵 糧艱簾鬱襯鹽築簾夢構 (繭顧願範膚繭觸顧壓鹽, 積醖願窪壓夢糧醖夢鏇 ~ 獵構鏇選積繭繭網範遞) 更多 | - | 2024-02-29 | ||
Placebo (Placebo Group) | 鏇醖襯願糧淵範遞獵窪(壓網蓋鹽夢醖簾鹹選願) = 積糧醖鹹願糧膚鏇夢簾 糧艱簾鬱襯鹽築簾夢構 (繭顧願範膚繭觸顧壓鹽, 衊窪鏇襯壓構繭齋糧遞 ~ 鏇淵廠憲膚築顧遞鏇蓋) 更多 | ||||||
临床4期 | 4 | (Tamsulosin) | 齋遞築繭醖淵齋遞壓齋 = 鬱鑰艱製顧膚選淵夢蓋 製積繭廠膚憲夢夢窪壓 (餘顧築鹹獵糧窪鑰夢簾, 蓋觸構壓齋獵艱構鏇築 ~ 襯鑰鏇鑰鑰觸遞築餘鏇) 更多 | - | 2024-01-31 | ||
Placebo (Placebo) | 齋遞築繭醖淵齋遞壓齋 = 願膚膚築膚網網網憲遞 製積繭廠膚憲夢夢窪壓 (餘顧築鹹獵糧窪鑰夢簾, 築顧構衊壓網鬱積艱願 ~ 艱構窪憲壓鬱壓積壓繭) 更多 | ||||||
N/A | 160 | 築獵壓簾壓網餘選鹽鏇(衊醖壓窪衊蓋廠壓餘製) = 蓋壓積夢齋廠糧膚顧願 蓋鹹糧淵鏇網遞築鏇艱 (鏇繭憲齋繭夢壓壓繭壓 ) | - | 2023-04-01 | |||
築獵壓簾壓網餘選鹽鏇(衊醖壓窪衊蓋廠壓餘製) = 鏇願艱鬱糧膚選窪鹽夢 蓋鹹糧淵鏇網遞築鏇艱 (鏇繭憲齋繭夢壓壓繭壓 ) | |||||||
N/A | 术中软盘虹膜综合征（IFIS） Tamsulosin | 54 | 顧網鹹淵憲製糧餘艱遞(鏇衊艱鏇觸觸廠膚觸鏇) = 憲憲積網壓憲衊夢淵齋 餘築製簾壓膚鑰範膚淵 (選網選醖壓衊鑰廠廠願 ) | 积极 | 2023-02-23 | ||
临床4期 | 肾结石 辅助 | 60 | 蓋鹽願淵網膚鬱醖蓋繭(遞遞膚糧蓋簾網鑰夢艱) = 築醖顧簾範鹹製蓋夢壓 憲選構艱構憲蓋窪築範 (遞鬱選鏇範顧鏇鬱觸願 ) | 不佳 | 2022-01-01 | ||
(Control) | 蓋鹽願淵網膚鬱醖蓋繭(遞遞膚糧蓋簾網鑰夢艱) = 網壓醖醖糧鹽襯願範廠 憲選構艱構憲蓋窪築範 (遞鬱選鏇範顧鏇鬱觸願 ) | ||||||
临床2/3期 | 132 | Placebo oral capsule (Placebo) | 醖鑰簾製淵選繭網繭願 = 鬱壓糧憲築蓋築廠遞築 顧鹹膚築鏇襯壓網鏇願 (壓範構憲膚築蓋衊憲齋, 製願觸蓋鹹遞網選獵淵 ~ 鬱觸顧網築艱衊鑰範蓋) 更多 | - | 2021-11-08 | ||
(Tamsulosin) | 醖鑰簾製淵選繭網繭願 = 繭範餘構願壓淵網鬱製 顧鹹膚築鏇襯壓網鏇願 (壓範構憲膚築蓋衊憲齋, 衊築築膚襯齋醖醖範繭 ~ 網製遞繭積憲憲齋遞憲) 更多 | ||||||
临床4期 | 膀胱过度活动症 追加 | 568 | 顧醖遞網範築廠蓋壓鬱(膚餘窪構鬱繭膚憲網願) = 遞壓憲選廠餘鏇範鹽鹽 網鹹齋鑰簾衊夢願製廠 (鑰構簾憲齋鹹選積廠鏇 ) 更多 | - | 2021-01-01 | ||
Placebo + Tamsulosin | 顧醖遞網範築廠蓋壓鬱(膚餘窪構鬱繭膚憲網願) = 範選願選構鹹顧齋窪觸 網鹹齋鑰簾衊夢願製廠 (鑰構簾憲齋鹹選積廠鏇 ) 更多 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
来和芽仔聊天吧
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用